Literature DB >> 1157223

Selective inhibition by des-1-Asp-8-lle-angiotensin ii of the steroidogenic response to restricted sodium intake in the rat.

C A Sarstedt, E D Vaughan, M J Peach.   

Abstract

Angiotensin III (des-1-Asp-angiotensin II) is a potent steriodogenic agent in many species. The effects of the heptapeptide in the adrenal zona glomerulosa are resistant to blockade by C-terminally substituted analogues of angiotensin II (1-Sar-8-Ile- or 1-Sar-8-Ala-octapeptides). For this reason, the effects of 7-Ile-angiotensin III, a C-terminally substituted analogue of the heptapeptide, and 1-Sar-8-Ile-angiotensin II on aldosterone biosynthesis in rabbit adrenal cortical cell suspensions and on urinary aldosterone excretion in sodium-deprived rats were studied. In the vitro studies, 7-Ile-angiotensin III was a better antagonist of angiotensin II- or angiotensin III-induced steroidogenesis than was 1-Sar-8-Ile-angiotensin II. In the rats, subcutaneously administered 1-Sar-8-Ile-angiotensin II (0.9 mumoles/kg) produced prolonged blockade of the pressor responses to exogenous angiotensin II. 70Ile-angiotensin III (0.9 mumoles/kg) had no effect on resting blood pressure or on blood pressure responses to angiotensin II infusions. At the doses studied, however, 7-Ile-angiotensin III caused a marked decrease (50%) in aldosterone excretion in sodium-deprived rats, but 1-Sar-8-Ile-angiotensin II had no effect on aldosterone excretion. In the sodium-deprived rats, the administration of 7-Ile-angiotensin Ile was not associated with an acute increase in plasma renin activity, but treatment with 1-Sar-8-Ile-angiotensin II resulted in a sixfold increase in plasma renin activity, but otensin III was not associated with an acute increase in plasma renin activity, but treatment with 1-Sar-8-Ile-angiotensin II resulted in a sixfold increase in plasma renin activity. These results are consistent with a role for angiotensin III in the control of aldosterone biosynthesis.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1157223     DOI: 10.1161/01.res.37.3.350

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  7 in total

1.  Specific receptors for des-Asp1-angiotensin II (("angiotensin III") in rat adrenals.

Authors:  M A Devynck; M G Pernollet; P G Matthews; M C Khosla; F M Bumpus; P Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

2.  Obligatory Metabolism of Angiotensin II to Angiotensin III for Zona Glomerulosa Cell-Mediated Relaxations of Bovine Adrenal Cortical Arteries.

Authors:  Phillip G Kopf; Sang-Kyu Park; Anja Herrnreiter; Christian Krause; Bernard P Roques; William B Campbell
Journal:  Endocrinology       Date:  2018-01-01       Impact factor: 4.736

3.  Angiotensin antagonists with increased specificity for the renal vasculature.

Authors:  K J Taub; W J Caldicott; N K Hollenberg
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808

4.  Activity of (des-Aspartyl1)-angiotensin II and angiotensin II in man. Differences in blood pressure and adrenocortical response during normal and low sodium intake.

Authors:  R M Carey; E D Vaughan; M J Peach; C R Ayers
Journal:  J Clin Invest       Date:  1978-01       Impact factor: 14.808

5.  Demonstration of different contractile mechanisms for angiotensin II and des-Asp1-angiotensin II in rabbit aortic strips.

Authors:  J A Ackerly; A F Moore; M J Peach
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

6.  Attenuation of angiotensin II- and III-induced aldosterone release by prostaglandin synthesis inhibitors.

Authors:  W B Campbell; C E Gomez-Sanchez; B V Adams; J M Schmitz; H D Itskovitz
Journal:  J Clin Invest       Date:  1979-12       Impact factor: 14.808

7.  Effect of three angiotensin II antagonists, [Sar1, Thr8]-, [Sar1, Ile8]- and [Sar1, Ala8]angiotensin II on blood pressure and endocrine factors in normal subjects.

Authors:  T Hata; T Ogihara; M Nakamaru; S Gotoh; K Masuo; S Saeki; A Kumagai; Y Kumahara
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.